Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nageatte Ibrahim

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 9, 2017
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanomaTeresa M Petrella, Caroline Robert, Erika Richtig, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesSowmya Ravi, Kristen Spencer, Mary Ruisi, et al.
The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Cancer Immunology Research|April 5, 2017
Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma PatientsMarlene Garcia-Neuer, Melina E Marmarelis, Sushrut R Jangi, et al.
Cancer Chemotherapy and Pharmacology|November 25, 2014
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myelomaAnthony W Tolcher, Amita Patnaik, Kyriakos P Papadopoulos, et al.
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Radiation Oncology (London, England)|June 24, 2014
The role of whole brain radiation therapy in the management of melanoma brain metastasesMichael A Dyer, Nils D Arvold, Yu-Hui Chen, et al.
Pigment Cell & Melanoma Research|August 3, 2016
Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferationBenjamin Izar, Cailin E Joyce, Stephanie Goff, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|October 9, 2017
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanomaTeresa M Petrella, Caroline Robert, Erika Richtig, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesSowmya Ravi, Kristen Spencer, Mary Ruisi, et al.
The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Cancer Immunology Research|April 5, 2017
Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma PatientsMarlene Garcia-Neuer, Melina E Marmarelis, Sushrut R Jangi, et al.
Cancer Chemotherapy and Pharmacology|November 25, 2014
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myelomaAnthony W Tolcher, Amita Patnaik, Kyriakos P Papadopoulos, et al.
British Journal of Cancer|September 12, 2018
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006Omid Hamid, Caroline Robert, Antoni Ribas, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Radiation Oncology (London, England)|June 24, 2014
The role of whole brain radiation therapy in the management of melanoma brain metastasesMichael A Dyer, Nils D Arvold, Yu-Hui Chen, et al.
Pigment Cell & Melanoma Research|August 3, 2016
Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferationBenjamin Izar, Cailin E Joyce, Stephanie Goff, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
Pageof 6